As genetic variability of the GLP1R gene was shown to influence the response to treatment with GLP-1 RAs, pharmacogenetic testing may contribute to personalized and, thus, more effective and safer treatment of T2DM and obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.